KR20260074394A - 수의과용 igg fc 변이체 - Google Patents

수의과용 igg fc 변이체

Info

Publication number
KR20260074394A
KR20260074394A KR1020267013181A KR20267013181A KR20260074394A KR 20260074394 A KR20260074394 A KR 20260074394A KR 1020267013181 A KR1020267013181 A KR 1020267013181A KR 20267013181 A KR20267013181 A KR 20267013181A KR 20260074394 A KR20260074394 A KR 20260074394A
Authority
KR
South Korea
Prior art keywords
seq
polypeptide
sequence
igg
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267013181A
Other languages
English (en)
Korean (ko)
Inventor
항준 장
람 누엔
용종 리
펀 치안
샤이어 지안 리
Original Assignee
엘랑코 유에스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65361820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20260074394(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 엘랑코 유에스 인코포레이티드 filed Critical 엘랑코 유에스 인코포레이티드
Publication of KR20260074394A publication Critical patent/KR20260074394A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020267013181A 2017-08-15 2018-08-15 수의과용 igg fc 변이체 Pending KR20260074394A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762545858P 2017-08-15 2017-08-15
US62/545,858 2017-08-15
PCT/IB2018/056142 WO2019035010A1 (en) 2017-08-15 2018-08-15 IGG VARIANTS FOR VETERINARY USE
KR1020207005513A KR102959451B1 (ko) 2017-08-15 2018-08-15 수의과용 igg fc 변이체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005513A Division KR102959451B1 (ko) 2017-08-15 2018-08-15 수의과용 igg fc 변이체

Publications (1)

Publication Number Publication Date
KR20260074394A true KR20260074394A (ko) 2026-05-22

Family

ID=65361820

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267013181A Pending KR20260074394A (ko) 2017-08-15 2018-08-15 수의과용 igg fc 변이체
KR1020207005513A Active KR102959451B1 (ko) 2017-08-15 2018-08-15 수의과용 igg fc 변이체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207005513A Active KR102959451B1 (ko) 2017-08-15 2018-08-15 수의과용 igg fc 변이체

Country Status (10)

Country Link
US (1) US12297272B2 (cg-RX-API-DMAC7.html)
EP (1) EP3668536A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020531002A (cg-RX-API-DMAC7.html)
KR (2) KR20260074394A (cg-RX-API-DMAC7.html)
CN (2) CN111182915A (cg-RX-API-DMAC7.html)
AU (3) AU2018318440A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020002871A2 (cg-RX-API-DMAC7.html)
CA (1) CA3071337A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020001707A (cg-RX-API-DMAC7.html)
WO (1) WO2019035010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
HUE062719T2 (hu) 2018-06-29 2023-11-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3866842A4 (en) * 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
WO2020139984A1 (en) * 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
KR20220066002A (ko) * 2019-03-20 2022-05-23 킨드레드 바이오사이언시스, 인코포레이티드 의학적 용도의 ngf 길항제
JP2022542275A (ja) * 2019-07-30 2022-09-30 キンドレッド バイオサイエンシズ インコーポレイテッド 動物用パルボウイルス抗体
KR102865175B1 (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN115135669B (zh) 2020-02-19 2026-05-19 硕腾服务有限责任公司 修饰的Fc区
US20240067738A1 (en) * 2020-03-18 2024-02-29 Elanco Us Inc. Anti-il4 receptor antibodies for veterinary use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
CA3173864A1 (en) * 2020-04-22 2021-10-28 Shyr Jiann Li Long-acting anti-il31 antibodies for veterinary use
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
EP4199942A4 (en) * 2020-08-24 2025-03-19 The Trustees of The University of Pennsylvania Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
CN112625093B (zh) * 2020-12-29 2022-12-23 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
EP4380974A1 (en) * 2021-08-06 2024-06-12 Petmedix Ltd. Antibody fc variants
AU2023415535A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions
WO2026039359A1 (en) * 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026038455A1 (ja) * 2024-08-14 2026-02-19 国立大学法人山口大学 細胞傷害活性及び細胞貪食活性を低減させた抗ネコ抗体

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6207383B1 (en) * 1998-07-27 2001-03-27 University Of Utah Research Foundation Mutations in and genomic structure of HERG—a long QT syndrome gene
US7297482B2 (en) * 1998-10-08 2007-11-20 Rigel Pharmaceuticals, Inc. Structurally biased random peptide libraries based on different scaffolds
AU2511901A (en) * 1999-12-23 2001-07-09 Universite De Geneve Basolateral sorting signal and inhibitors thereof
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2004321100A (ja) 2003-04-25 2004-11-18 Rikogaku Shinkokai ＩｇＧのＦｃ領域を含むタンパク質の変異体
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP2008525452A (ja) 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Ｇｌｐ−１類似体融合蛋白質製剤
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
CN101273134B (zh) 2005-07-27 2012-01-04 王庆华 用于预防和治疗ⅰ型和ⅱ型糖尿病的组合物和方法
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
KR20100020516A (ko) 2007-07-10 2010-02-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1-ｆｃ 융합 단백질 제제
MX2011006870A (es) * 2008-12-23 2011-07-19 Genentech Inc Variantes de inmunoglobulina con union alterada a proteina a.
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
US20130108623A1 (en) 2010-03-29 2013-05-02 Zymeworks Inc Antibodies with Enhanced or Suppressed Effector Function
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
SG10201500957QA (en) 2011-05-06 2015-04-29 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
CA2842067A1 (en) 2011-07-19 2013-01-24 The National Institute For Biotechnology In The Negev, Ltd. Novel il-17r-ecd mutants
US9790280B2 (en) 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
JP2015509714A (ja) * 2012-02-22 2015-04-02 エヌヴィーアイピー プロプライエタリー リミテッド 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
CA2879814A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
WO2014093387A1 (en) 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EP3027647A4 (en) 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
AU2014368453B2 (en) * 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
EP3104887A4 (en) 2014-02-11 2017-03-15 Beijing Advaccine Biotechnology Co. Ltd. Vaccines with interleukin-17 as an adjuvant
WO2016044189A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
RU2713131C1 (ru) 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
RU2728710C2 (ru) 2015-10-19 2020-07-30 Новартис Аг Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)
ES3014160T3 (en) 2015-12-18 2025-04-21 Intervet Int Bv Caninized human antibodies to human and canine il-4r alpha
ES2871117T3 (es) 2016-01-26 2021-10-28 Defensin Therapeutics Aps Procedimientos para modular la microbiota intestinal
CA3014461C (en) 2016-02-18 2023-02-28 Elanco Us Inc. Chimeric canine anti-cd20 antibody
CN109844124B (zh) 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
EP3481413A4 (en) 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3526246A1 (en) 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
WO2018102668A1 (en) 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
JP7657548B2 (ja) * 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
WO2018236728A1 (en) 2017-06-18 2018-12-27 Kindred Biosciences, Inc. ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
HUE062719T2 (hu) 2018-06-29 2023-11-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások
JP2022500037A (ja) 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
EP3866842A4 (en) 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
EP3870601A4 (en) 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
WO2020116560A1 (ja) 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
JP2022511882A (ja) 2018-12-12 2022-02-01 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のためのエリスロポエチンアナログ
WO2020139984A1 (en) 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
KR20220066002A (ko) 2019-03-20 2022-05-23 킨드레드 바이오사이언시스, 인코포레이티드 의학적 용도의 ngf 길항제
JP7762645B2 (ja) 2019-08-22 2025-10-30 シダラ セラピューティクス インコーポレーテッド バリアントｆｃドメイン及びその使用
CN114364796B (zh) 2019-09-02 2023-07-11 甘李药业股份有限公司 嵌合蛋白
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
IL297287A (en) 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
EP4136109A1 (en) 2020-04-17 2023-02-22 Zoetis Services LLC Feline antibody variants
MX2022013149A (es) 2020-04-22 2023-02-09 Kindred Biosciences Inc Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
CA3173864A1 (en) 2020-04-22 2021-10-28 Shyr Jiann Li Long-acting anti-il31 antibodies for veterinary use
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
EP4166574A4 (en) 2020-06-10 2025-01-15 Bica Therapeutics Inc. FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE
EP4172193A1 (en) 2020-06-29 2023-05-03 Zoetis Services LLC Feline antibody variants for improving stability
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
WO2022046941A1 (en) 2020-08-26 2022-03-03 Angiex, Inc. Antimitotic tetrapeptide-antibody conjugates and methods of using same

Also Published As

Publication number Publication date
US12297272B2 (en) 2025-05-13
JP2026048634A (ja) 2026-03-17
EP3668536A4 (en) 2021-05-26
CN119390821A (zh) 2025-02-07
RU2020110584A (ru) 2021-09-17
US20200362034A1 (en) 2020-11-19
AU2018318440A1 (en) 2020-02-13
KR20200057701A (ko) 2020-05-26
WO2019035010A1 (en) 2019-02-21
KR102959451B1 (ko) 2026-04-30
CA3071337A1 (en) 2019-02-21
RU2020110584A3 (cg-RX-API-DMAC7.html) 2021-12-15
BR112020002871A2 (pt) 2020-07-28
AU2025220819A1 (en) 2025-09-25
MX2020001707A (es) 2020-03-20
EP3668536A1 (en) 2020-06-24
JP2020531002A (ja) 2020-11-05
AU2023226676B2 (en) 2025-05-22
AU2023226676A1 (en) 2023-09-28
CN111182915A (zh) 2020-05-19

Similar Documents

Publication Publication Date Title
KR102959451B1 (ko) 수의과용 igg fc 변이체
JP6960832B2 (ja) Ｆｇｆ２１突然変異体及びその使用
KR102935714B1 (ko) 수의과 용도를 위한 IgG Fc 변이체
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US10287336B2 (en) Feline erythropoietin receptor agonists
US20220169740A1 (en) NGF Antagonists for Medical Use
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
CN113423721A (zh) 兽用促红细胞生成素类似物
RU2814952C2 (ru) ВАРИАНТЫ IgG-FC ДЛЯ ПРИМЕНЕНИЯ В ВЕТЕРИНАРИИ
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
RU2850882C2 (ru) Варианты fc igg для ветеринарного применения
WO2025076095A2 (en) Long-acting glucagon-like peptide 1 receptor (glp1r) agonists for veterinary use

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201